1. Efron D, Jarman F, Barker M. Methylphenidate versus dexamphetamine in children with attention deficit hyperactivity disorder: A double-blind, crossover trial. Pediatrics 1997; 100(6): E6
2. Efron D, Jarman F, Barker M. Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial. Pediatrics 1997; 100(4): 662-666
3. Schubiner H, Saules KK, Arfken CL, Johanson CE, Schuster CR, Lockhart N et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Exp Clin Psychopharmacol 2002; 10(3): 286-294
4. Greenhill L, Kollins S, Abikoff H et al. Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. JAACAP 2006; 45: 1284-1293
5. Correl CU. Weight Gain and Metabolic Effects of Mood Stabilizers and Antipsychotics in Pediatric Bipolar Disorder: A Systematic Review and Pooled Analysis of Short-Term Trials. JAACAP 2007; 46: 687-700
6. Malone RP, Maislin G, Choudhury MS, Gifford C, Delaney MA. Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness. JAACAP 2002; 41(2): 140-147
7. Faraone SV, Biederman J, Morley CP, Spencer TJ. Effect of stimulants on height and weight: a review of the literature. JAACAP 2008; 47(9): 994-1009
8. Gilbert DL, Batterson JR, Sethuraman G, Sallee FR. Tic reduction with risperidone versus pimozide in a randomized, double-blind, crossover trial. JAACAP 2004; 43(2): 206-214
9. Findling RL, Robb A, Nyilas M, Forbes RA, Jin N, Ivanova S, Marcus R, McQuade RD, Iwamoto T, Carson WH. A multiple-center, randomized, double blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry 2008; 165(11): 1432-41
10. Devinsky O, Honigfeld G, Patin J. Clozapine-related seizures. Neurology 1991; 41(3):369-371
11. Friedman RA, Leon AC. Expanding the black box – depression, anti-depressants and the risk of suicide. N Engl J Med 2007; 356(23): 2343-6
12. Cahn W, Ramlal D, Bruggeman R, de Haan L, Scheepers FE, van Soest MM, Assies J, Slooff CJ. Preventie en behandeling van somatische complicaties bij antipsychoticagebruik. Tijdschrift voor Psychiatrie 2008; 50(9): 579-591
13. Van Aerde KJ, Kalverdijk LJ, Reimer AG, Widdershoven JA. QT interval prolongation and psychotropic drugs in children and adolescents: proposed quideline. Ned Tijdschr Geneeskd 2008; 152(32): 1765-70
14. Vorstman J, Lahuis B, Buitelaar JK. SSRIs associated with behavioral activation and suicidal ideation. JAACAP 2001; 40(12): 1364-1365
15. Ruth U, Mayer-Rosa J, Schlamp D, Freisleder FJ. Tourette´s syndrome and antidepressant therapy: exacerbation of nervous tics with paroxetine. Z Kinder Jugendpsychiatr Psychother 2000; 28(2): 105-108
16. Wilens TE, Biederman J, Baldessarini RJ, Geller B, Schleifer D, Spencer TJ et al. Cardiovascular effects of therapeutic doses of tricyclic antidepressants in children and adolescents. JAACAP 1996; 35(11): 1491-1501
17. Gutgesell H, Atkins D, Barst R, Buck M, Franklin W, Humes R et al. Cardiovascular monitoring of children and adolescents receiving psychotropic drugs: A statement for healthcare professionals from the Committee on Congenital Cardiac Defects, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 1999; 99(7): 979-982
18. Richardson G, Wang-Weigand S. Effects of long-term exposure to ramelteon, a melatonin receptor agonist, on endocrine function in adults with chronic insomnia. Hum Psychopharmacol 2009; 24(2): 103-11
